Literature DB >> 11886960

Plasminogen activator inhibitor type-1 deficiency attenuates murine antigen-induced arthritis.

K Van Ness1, V Chobaz-Péclat, M Castellucci, A So, N Busso.   

Abstract

OBJECTIVE: To examine the role of plasminogen activator inhibitor type-1 (PAI-1), the major fibrinolytic inhibitor, in vivo during murine antigen-induced arthritis (AIA).
METHODS: AIA was induced in PAI-1-deficient mice and control wild-type mice. Arthritis severity was evaluated by technetium 99m (99mTc) uptake in the knee joints and by histological scoring. Intra-articular fibrin deposition was examined by immunohistochemistry and synovial fibrinolysis quantitated by tissue D-dimer measurements and zymograms.
RESULTS: Joint inflammation, quantitated by 99mTc uptake, was significantly reduced in PAI-1(-/-) mice on day 7 after arthritis onset (P<0.01). Likewise, synovial inflammation, evaluated by histological scoring, was significantly decreased in PAI-1-deficient mice on day 10 after arthritis onset (P<0.001). Articular cartilage damage was significantly decreased in PAI-1(-/-) mice, as shown by histological grading of safranin-O staining on day 10 after arthritis onset (P<0.005). Significantly decreased synovial accumulation of fibrin was observed by day 10 in arthritic joints of PAI-1(-/-) mice (P<0.005). Accordingly, the synovial tissue content of D-dimers, the specific fibrin degradation products generated by plasmin, were increased in PAI-1(-/-) mice (P<0.02). Finally, as expected, PA activity was increased in synovial tissues from PAI-1(-/-) mice, as shown by zymographic analysis.
CONCLUSIONS: These results indicate that deficiency of PAI-1 results in increased synovial fibrinolysis, leading to reduced fibrin accumulation in arthritic joints and reduced severity of AIA.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11886960     DOI: 10.1093/rheumatology/41.2.136

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  7 in total

1.  Fibrinolysis is down-regulated in mouse collagen-induced arthritis, but its normalization does not alleviate the course of disease.

Authors:  Jakub Kwieciński; Elisabet Josefsson; Tao Jin
Journal:  Inflamm Res       Date:  2011-07-24       Impact factor: 4.575

2.  Discrepancy between mRNA and protein expression of tumour suppressor maspin in synovial tissue may contribute to synovial hyperplasia in rheumatoid arthritis.

Authors:  J Schedel; O Distler; M Woenckhaus; R E Gay; B Simmen; B A Michel; U Müller-Ladner; S Gay
Journal:  Ann Rheum Dis       Date:  2004-10       Impact factor: 19.103

Review 3.  Serine proteinases in the turnover of the cartilage extracellular matrix in the joint: implications for therapeutics.

Authors:  David J Wilkinson; Maria Del Carmen Arques; Carmen Huesa; Andrew D Rowan
Journal:  Br J Pharmacol       Date:  2018-03-30       Impact factor: 8.739

4.  Plasminogen activator inhibitor-type I gene deficient mice show reduced influx of neutrophils in ventilator-induced lung injury.

Authors:  Esther K Wolthuis; Alexander P J Vlaar; Jorrit-Jan H Hofstra; Joris J T H Roelofs; Vivian de Waard; Nicole P Juffermans; Marcus J Schultz
Journal:  Crit Care Res Pract       Date:  2011-07-14

5.  A suppressive effect of prostaglandin E2 on the expression of SERPINE1/plasminogen activator inhibitor-1 in human articular chondrocytes: An in vitro pilot study.

Authors:  Kayo Masuko; Minako Murata; Naoya Suematsu; Kazuki Okamoto; Kazuo Yudoh; Hiroyuki Shimizu; Moroe Beppu; Hiroshi Nakamura; Tomohiro Kato
Journal:  Open Access Rheumatol       Date:  2009-04-17

Review 6.  Transcriptional Regulation of Osteoclastogenesis: The Emerging Role of KLF2.

Authors:  Daniela Rolph; Hiranmoy Das
Journal:  Front Immunol       Date:  2020-05-13       Impact factor: 7.561

Review 7.  The Urokinase Plasminogen Activation System in Rheumatoid Arthritis: Pathophysiological Roles and Prospective Therapeutic Targets.

Authors:  Benjamin J Buckley; Umar Ali; Michael J Kelso; Marie Ranson
Journal:  Curr Drug Targets       Date:  2019       Impact factor: 3.465

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.